Pentosan Polysulfate Sodium and Maculopathy in Patients with Interstitial Cystitis: A Systematic Review and Meta-Analysis

被引:0
|
作者
Lee, Jongsoo [1 ]
Kim, Yun Jin [2 ]
Lee, Konghee [3 ]
Kim, Young Kook [4 ,5 ]
Rhee, Taeho Greg [6 ,7 ]
Shim, Sung Ryul [8 ,9 ,10 ]
Kim, Jae Heon [11 ]
机构
[1] Yonsei Univ, Coll Med, Severance Hosp, Dept Urol, Seoul, South Korea
[2] Soonchunhyang Univ, Bucheon Hosp, Dept Pathol, Bucheon 14584, South Korea
[3] Zenit Urol Clin, Chang Won, South Korea
[4] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Ophthalmol, Seoul, South Korea
[5] EyeLight Data Sci Lab, Seoul, South Korea
[6] Yale Sch Med, Dept Psychiat, New Haven, CT USA
[7] Univ Connecticut, Sch Med, Dept Publ Hlth Sci, Farmington, CT USA
[8] Konyang Univ, Coll Med, Dept Biomed Informat, 158 Gwanjeodong Ro, Daejeon 35365, South Korea
[9] Konyang Univ Hosp, Konyang Med Data Res Grp KYMERA, Daejeon 35365, South Korea
[10] Konyang Univ Hosp, Myunggok Med Res Ctr, Daejeon, South Korea
[11] Soonchunhyang Univ, Coll Med, Dept Urol, Seoul Hosp, 59 Daesagwan Ro, Seoul 04401, South Korea
关键词
Cystitis; interstitial; Drug-related side effects and adverse reactions; Macular degeneration; Pentosan sulfuric polyes- ter; Retinal diseases; PREVALENCE; SYMPTOMS;
D O I
10.5534/wjmh.240295
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
Purpose: Pentosan polysulfate sodium (PPS) is the only pharmacological intervention approved by the US Food and Drug Administration for treating interstitial cystitis (IC) to date. However, PPS may induce an adverse event, maculopathy, which can be a significant challenge. To determine the risk of PPS-induced maculopathy in patients with IC. Materials and Methods: PubMed and Embase were systematically searched through July 2024. Two authors also independently and manually searched all relevant studies. We included national level cohort studies using healthcare claim big data or real-world data with the following criteria: (1) patients diagnosed with IC; (2) interventions included PPS as an active treatment; (3) comparisons were specified as non-PPS interventions; and (4) the primary outcome of interest was the risk of maculopathy. The pairwise meta-analysis was performed to compare the PPS treatment group with control used in IC. The primary outcome measure was the hazard ratio (HR), odds ratio (OR), and proportional report ratio (PRR) of maculopathy after receiving the PPS treatment, as compared to non-PPS interventions. Results: A comprehensive literature search was conducted, and identified 6 studies with 411,098 patients. The pooled risk for maculopathy due to PPS in patients with IC was significant (HR, 1.678; 95% confidence interval [95% CI], 1.066-2.642]). The heterogeneity test produced a Higgins' I-squared statistic, which was 83.6%. In the subgroup analysis of follow-up period of less than 5 years (HR, 1.285; 95% CI, 1.139-1.449) and more (HR, 1.341; 95% CI, 1.307-1.375) were statistically significant, indicating that the patients with IC who had a long-term PPS treatment were more likely to have maculopathy than the control groups. Conclusions: This is the first study to investigate the relationship between PPS and its association with the risk of maculopathy in patients with IC through a systematic review and meta-analysis.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Pentosan polysulfate - A review of its use in the relief of bladder pain or discomfort in interstitial cystitis
    Anderson, Vanessa R.
    Perry, Caroline M.
    DRUGS, 2006, 66 (06) : 821 - 835
  • [22] Potential New Phenotypic Presentation of Pentosan Polysulfate Sodium Maculopathy
    Ghiam, Sean
    Pirouz, Ash
    Adrean, Sean D.
    JOURNAL OF VITREORETINAL DISEASES, 2024, 8 (06) : 735 - 739
  • [23] Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate Sodium
    Pearce, William A.
    Chen, Rui
    Jain, Nieraj
    OPHTHALMOLOGY, 2018, 125 (11) : 1793 - 1802
  • [24] New Study Results: No Connection between Pentosan Polysulfate and Maculopathies in Patients with Interstitial Cystitis
    不详
    UROLOGE, 2020, 59 (02): : 228 - 228
  • [25] A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis
    Sant, GR
    Propert, KJ
    Hanno, PM
    Burks, D
    Culkin, D
    Diokno, AC
    Hardy, C
    Landis, JR
    Mayer, R
    Madigan, R
    Messing, EM
    Peters, K
    Theoharides, TC
    Warren, J
    Wein, AJ
    Steers, W
    Kusek, JW
    Nyberg, LM
    JOURNAL OF UROLOGY, 2003, 170 (03): : 810 - 815
  • [26] Efficacy of pentosan polysulfate for the treatment of interstitial cystitis/bladder pain syndrome: results of a systematic review of randomized controlled trials
    van Ophoven, Arndt
    Vonde, Kirsten
    Koch, Winfried
    Auerbach, Guenter
    Maag, Klaus P.
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (09) : 1495 - 1503
  • [28] Intravesical instillation of pentosan polysulfate encapsulated in a liposome nanocarrier for interstitial cystitis
    Lander, Elliot B.
    See, Jackie R.
    AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY, 2014, 2 (02): : 145 - 148
  • [29] INFLUENCE OF OCULAR COMPLICATION RISK IN PENTOSAN POLYSULFATE USE FOR INTERSTITIAL CYSTITIS
    Kaefer, Daniela
    Lee, Victoria
    Limbrick, Bree'ava
    Kim, Ja-Hong
    NEUROUROLOGY AND URODYNAMICS, 2021, 40 : S179 - S179
  • [30] Time to initiation of pentosan polysulfate sodium treatment after interstitial cystitis diagnosis: Effect on symptom improvement
    Nickel, J. Curtis
    Kaufman, David M.
    Zhang, Huabin F.
    Wan, George J.
    Sand, Peter K.
    UROLOGY, 2008, 71 (01) : 57 - 61